December 01, 2012
1 min read

Lung specialist joins Ohio State

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

David P. Carbone, MD, PhD 

David P. Carbone

David P. Carbone, MD, PhD, will develop and lead a new thoracic oncology center at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The thoracic oncology center will be designed to bring physicians and scientists together to develop new, targeted approaches to treating and curing lung cancer.

Carbone’s research has focused on the molecular genetics of lung tumors, including the specific cells and genetic markers in each patient’s lung cancer, and treatments and drugs that target specific tumor cells.

“As a lung cancer specialist, I’m determined to make a difference and to contribute to knowledge in the field by training other physicians, doing research and caring for patients,” Carbone said in a press release. “By taking a team approach and combining research with optimal clinical care, we can improve the lives of lung cancer patients.”

Carbone previously served as professor of medicine and cancer biology at Vanderbilt University. He also directed the experimental therapeutics program, as well as the thoracic and head and neck cancer program, at Vanderbilt-Ingram Cancer Center.

“David is truly a world leader, not just in his research on the cellular and molecular levels of lung cancer, but also in translational research, taking those discoveries from the bench to the bedside,” Michael A. Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. “His vision for integrating laboratory and clinical research with patient care will further our translational research efforts in lung cancer, and ultimately will improve the lives of lung cancer patients.”